Drug delivery device having dose indicator
The drug delivery device addresses the challenge of determining medication remaining by using an audible indicator that signals completion of administration, enhancing user confidence and accuracy.
Patent Information
- Application Number
- JP2024145202
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-10-05
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Drug delivery devices such as autoinjectors often lack clear indicators for the user to determine the amount of medication remaining, leading to premature removal or prolonged use, causing discomfort and anxiety.
A drug delivery device equipped with an audible indicator that engages the drive assembly to generate a sound when the medication is expelled, ensuring accurate administration.
The audible indicator provides a clear auditory signal when the medication is fully administered, reducing user anxiety and ensuring complete dosage delivery.
Smart Images

Figure 2024164209000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS Priority is claimed to U.S. Provisional Patent Application No. 62 / 742,066, filed October 5, 2018, the entire contents of which are incorporated herein by reference.
[0002] The present disclosure relates generally to drug delivery devices and, more particularly, to the creation and operation of dosage indicators for drug delivery devices. [Background technology]
[0003] Drug delivery devices such as autoinjectors and on-body injectors offer several advantages in the delivery of medications and / or therapies, including, for example, ease of use when compared to traditional delivery methods using traditional syringes.
[0004] Autoinjectors may be used to deliver many different drugs with various viscosities and / or desired amounts. Due to the aversion to exposed needles and possible associated health and safety issues, various types of injectors and other devices have been developed to hide the needle from the user, automate the injection process to assist the user in performing the injection, and ensure reliable delivery of the drug to ensure patient safety. Thus, many of these devices provide limited visual access to the internal structure of the device due to the complexity of the device and to alleviate user concerns. As a result, the user may not know exactly how much drug remains in the device and may therefore prematurely remove the device from the injection site before administering the entire dose. Conversely, the user may take the opposite approach by holding the device against the injection site for an excessively long time to ensure that the entire dose has been administered. Doing so may cause the user discomfort, doubt, and / or anxiety. Summary of the Invention [Means for solving the problem]
[0005] According to a first aspect, the drug delivery device includes a housing defining a shell having a proximal end, a distal end, and a longitudinal axis extending between the proximal end and the distal end, a needle assembly at least partially disposed within the housing at the proximal end, a drive assembly at least partially disposed within the housing and operably coupled to the needle assembly, and an audible indicator operably coupled to the drive assembly. The needle assembly includes a syringe containing a medicament and a needle or cannula. The drive assembly is movable between an initial position and a second position that results in ejection of the medicament from the syringe. When the drive assembly is positioned at the second position, the audible indicator engages the drive assembly to generate an audible sound indicating that the medicament has been ejected from the syringe. In some forms, the audible indicator is additionally adapted to at least partially disengage from the drive assembly upon initiation of movement of the drive assembly from the first position toward the second position.
[0006] In some forms, the drive assembly includes a plunger rod having a first end, a second end, and a first detent positioned at the second end. The drive assembly may further include a second detent positioned a distance between the first end and the second end.
[0007] In some examples, the audible indicator may be in the form of an elastomeric ring having an engagement tab. The audible indicator may be made of at least one of a polymeric or metallic material. The engagement tab is adapted to engage a first detent and / or a second detent of the plunger rod. In other examples, the drive assembly may additionally include a magnetic member and the audible indicator may include a metallic member. In these examples, the metallic member engages the magnetic member to generate an audible sound when the drive assembly is positioned in the second position.
[0008] In some forms, the audible indicator may be in the relaxed configuration when the drive assembly is in the second position. Further, in some examples, the audible indicator may be in the relaxed configuration when the drive assembly is in the initial position.
[0009] According to a second aspect, a drug delivery device includes a housing defining a shell having a proximal end, a distal end, and a longitudinal axis extending between the proximal and distal ends, a needle assembly at least partially disposed within the housing at the proximal end, a drive assembly at least partially disposed within the housing and operably coupled to the needle assembly, and an audible indicator operably coupled to the drive assembly. The needle assembly includes a syringe containing a medicament and a needle or cannula. The drive assembly is movable between an initial position and a second position that results in ejection of the medicament from the syringe. Upon completion of delivery of the medicament through the needle assembly, the audible indicator engages the drive assembly to generate an audible sound indicating that the medicament has been ejected from the syringe.
[0010] The above needs are met, at least in part, by the provision of a torque-driven drug delivery device as described in the following detailed description, particularly when studied in conjunction with the drawings. [Brief description of the drawings]
[0011] [Figure 1a] 1 illustrates a cross-sectional view of an exemplary torque-driven drug delivery device having an audible indicator according to various embodiments. [Figure 1b] 1 illustrates a top cross-sectional view of a portion of the exemplary drug delivery device of FIG. 1a showing an audible indicator in a relaxed state according to various embodiments. [Figure 2a] 1A and 1B illustrate cross-sectional views of the exemplary drug delivery device of FIGS. 1A and 1B during drug administration according to various embodiments. [Figure 2b] 2b illustrates a top cross-sectional view of a portion of the exemplary drug delivery device of FIG. 2a showing an audible indicator in a stressed state according to various embodiments. [Figure 3a]1A-1B illustrate cross-sectional views of the exemplary drug delivery device of FIGS. 1a-2b upon completion of administration of a drug according to various embodiments. [Figure 3b] 3b illustrates a top cross-sectional view of a portion of the exemplary drug delivery device of FIG. 3a showing engagement of an audible indicator with a drive mechanism according to various embodiments. [Figure 4] 1 illustrates a perspective view of a portion of the exemplary drug delivery device of FIGS. 1a-3b according to various embodiments. [Diagram 5] 1 illustrates a cross-sectional view of an exemplary drug delivery device showing engagement of an audible indicator with a drive mechanism according to various embodiments. [Figure 6a] 1 illustrates a cross-sectional view of a second exemplary drug delivery device in an initial state according to various embodiments. [Figure 6b] 1 illustrates a cross-sectional view of a second exemplary drug delivery device in a second state according to various embodiments. [Figure 7a] 1 illustrates a cross-sectional view of a third exemplary drug delivery device in an initial state according to various embodiments. [Figure 7b] 7a-7c illustrate plan cross-sectional views of a portion of the exemplary drug delivery device of FIG. 7a according to various embodiments. [Figure 7c] 7a and 7b illustrate cross-sectional views of the exemplary drug delivery device of FIG. 7a and FIG. 7b in a second state according to various embodiments. [Figure 7d] 7c according to various embodiments. FIG. [Figure 8a] 1 illustrates a cross-sectional view of a fourth exemplary drug delivery device in an initial state according to various embodiments. [Figure 8b] 8a-8c illustrate perspective views of a portion of the exemplary drug delivery device of FIG. 8a according to various embodiments. [Figure 8c] 8a-8c illustrate perspective views of alternative portions of the exemplary drug delivery device of FIG. 8a according to various embodiments; [Figure 9a] 1 illustrates a cross-sectional view of a fifth exemplary drug delivery device in an initial state according to various embodiments. [Figure 9b]9a-9c illustrate plan cross-sectional views of a portion of the exemplary drug delivery device of FIG. 9a according to various embodiments. [Figure 9c] 9a and 9b illustrate cross-sectional views of the exemplary drug delivery device of FIG. 9a and FIG. 9b in a dosing state in accordance with various embodiments. [Figure 9d] 9a-9c in a cross-sectional view of the exemplary drug delivery device in an end-dosing state according to various embodiments; [Figure 10a] 14 illustrates a cross-sectional view of a sixth exemplary drug delivery device in an initial state according to various embodiments. [Figure 10b] 10a-10c illustrate plan cross-sectional views of a portion of the exemplary drug delivery device of FIG. 10a according to various embodiments. [Figure 10c] 10a and 10b illustrate cross-sectional views of the exemplary drug delivery device of FIG. 10a and FIG. 10b in a dispensed state in accordance with various embodiments. [Figure 10d] 10a-10c depict cross-sectional views of the exemplary drug delivery device of FIG. 10a-c in an end-dosing state according to various embodiments. [Figure 11a] 13 illustrates a cross-sectional view of a seventh exemplary drug delivery device in an initial state according to various embodiments. [Figure 11b] 12 illustrates a cross-sectional view of the exemplary drug delivery device of FIG. 11 in an end-of-dosing state in accordance with various embodiments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] Those skilled in the art will appreciate that elements in the figures are depicted for simplicity and clarity and are not necessarily drawn to scale. For example, the dimensions and / or relative positions of some of the elements in the figures may be exaggerated relative to other elements to help improve understanding of the various embodiments of the present invention. Also, common but well-understood elements that are useful or necessary in commercially feasible embodiments are often not shown in order to not overly distract from the illustrations of these various embodiments. Furthermore, it will be appreciated that certain acts and / or steps may be described or shown in a particular occupying order, although those skilled in the art will appreciate that such specificity with respect to order is not actually required. The terms and expressions used herein have the ordinary technical meanings, as set forth above, that would be given to such terms and expressions by those skilled in the art, unless a different specific meaning is explained herein.
[0013] Generally, according to these various embodiments, the injector includes a housing, a reservoir or syringe assembly that contains the medication to be injected into the user, and a rotatable drive or actuation assembly that uses a torque spring to inject the medication into the user. Upon completion of administration of the medication, an audible indicator emits a sound indicating the end of medication.
[0014] 1a and 1b, an exemplary autoinjector 1000 is provided. The injector 100 is a simplified version of a typical device and therefore does not show all of the necessary components and / or features of a drug delivery device. The injector 100 includes a housing 102 defining a shell, a needle assembly 110 at least partially disposed within the shell 102, a drive assembly 120 also at least partially disposed within the shell 102, and an audible indicator 140 at least partially disposed within the shell 102. The shell 102 includes a proximal end 102a and a distal end 102b and defines a longitudinal axis "L" extending between the proximal end 102a and the distal end 102b.
[0015] The needle assembly 110 generally includes a syringe barrel 112 disposed at or near the proximal end 102a of the shell 102 and housing a medicament 113, and a needle or cannula 114. The needle assembly 110 may include any number of additional components, such as, for example, one or more side walls, an opening that allows the medicament 113 to pass through the needle or cannula 114, a return spring, a shielding member, a filter member, etc., which will not be described in detail for the sake of brevity. A portion of the syringe barrel 112 may be open to accommodate a portion of the drive assembly 120, which will be described in more detail below. The syringe barrel 112 may have any desired shape and / or size to accommodate various amounts of the medicament 113. In some examples, the syringe barrel 112 may be made of a cyclic olefin polymer ("COP"). Other examples are possible.
[0016] The drive assembly 120 may include any number of components movable between an initial position and a second position that effects the ejection of the medicament 113 from the syringe barrel 112. For example, the drive assembly 120 may include a nut 122 positioned adjacent the syringe barrel 112, a trigger ring 124, a plunger rod guide 126, a plunger rod assembly 130, and a drive mechanism in the form of a torque spring or spiral spring 136. In general, the portions of the drive assembly 120 may be fixedly coupled to the shell 102 by any number of ways. In some configurations, the nut 122 may be integrally formed with the shell 102 and may include a threaded opening 122a. The trigger ring 124 is configured to selectively engage the nut 122 and move axially. In the illustrated example, the trigger ring 124 may be in the form of a generally cylindrical ring having a generally circular inner surface and any number of ridges, protrusions, and grooves disposed around and / or within the circumference of the ring. The trigger ring 124 may be coupled to the housing 102 by any number of techniques.
[0017] Plunger rod guide 126 includes a rod portion 127, a base portion 128 coupled to rod portion 127, and a slot 129. Plunger rod guide 126 includes an opening 126a extending at least partially through rod portion 127, and base portion 128. Base portion 128 can have any number of protrusions or tabs extending therefrom to form a slidable engagement with trigger ring 124.
[0018] The plunger rod assembly 130 includes a plunger rod 131 and a plunger 133 movable along the longitudinal axis L of the housing 102. The plunger rod 131 has a threaded portion 131a that is threadably coupled to the plunger rod guide 126 and the threaded opening 122a of the nut 122. The plunger rod 131 extends between a first end 131b and a second end 131c that defines a first detent or notch 134, which will be described in more detail below. The plunger rod 131 may additionally define a second detent or notch 135 spaced a distance between the first end 131b and the second end 131c. In some approaches, the plunger rod assembly 130 may further include a washer (not shown) that minimizes friction losses between the rotation of the plunger rod 131 and the non-rotating plunger 133, and may be used to adjust the amount of medicament 113 based on the thickness of the washer. Thus, various loadings of medicament 113 may be used in the same device 100.
[0019] The rod portion 127 of the plunger rod guide 126 is coupled to the plunger rod assembly 130 in any number of ways, including, for example, by a splined connection or a grooved configuration that allows the plunger rod assembly 130 to be axially displaced relative to the plunger rod guide 126. The plunger rod guide 126 thus guides the rotational movement of the plunger rod assembly 130. The threaded portion 131a of the plunger rod 131, and similarly the threaded opening 122a of the nut 122, may have a thread pitch suitable for any desired drug delivery rate or force / torque combination when driven by the drive mechanism 136. Relative rotation of the plunger rod 131 and the nut 122 advances the plunger rod 131 axially toward the proximal end 102a of the housing 102. The plunger 133 has an upper surface 133a disposed adjacent the syringe barrel 112.
[0020] In the illustrated example, the drive mechanism 136 is in the form of a spiral or torque spring 136 coupled to the rod portion 127 of the plunger rod guide 126 by any known means and exerts a torque on the plunger rod guide 126 to rotate it about the axis L. In some examples, the torque spring 136 may have many turns to provide the appropriate rotational movement required to expel the drug from the syringe barrel 112, but further parameters in the spring design, such as material properties and any applied heat treatments, may affect the torque output of the spring. Pre-shaping of the torque spring 136 may also affect its performance. As an example, in an autoinjector, a pre-stressed spring may be preferred because the pre-stressing process generally increases the torque output of the spring by first coiling the spring in the opposite direction to the intended operating conditions, thereby creating a permanent strain in the steel bands. This strain maximizes the stress in the material, thereby increasing the torque. Such an increase in torque is beneficial in minimizing the size and weight of the device.
[0021] The threaded connection between the plunger rod 131 and the nut 122 provides a conversion between the input torque and the output axial force of the torque spring 136. Providing a high number of turns for the torque spring 136 reduces the overall torque and reduces the change between the starting and ending torque compared to a linear spring with comparable transmission specifications or other torsion springs with fewer turns and smaller pitch. In addition, the threads of the plunger rod 131 and the nut 122 can have a smaller pitch with an increased number of turns while still achieving a similar linear motion of the plunger rod assembly 130. With a smaller thread pitch, less input torque is required to provide the same output as a high pitch thread and high torque spring. Thus, the high number of turns (e.g., about 1 to about 30 turns) and low torque system described herein allows for reduced actuation forces since actuation forces are directly related to the input torque that must be used to drive the plunger rod assembly 130. Additionally, reduced internal structural forces are required to resist torque from torque spring 136 during storage (e.g., prior to use), allowing for the use of smaller injector designs and less expensive raw materials. Additionally, the threaded connection between plunger rod 131 and nut 122 allows threaded plunger rod 131 to be adjusted to accommodate different amounts of drug stored in syringe barrel 112. If desired, threaded plunger rod 131 may be first installed at a lower position in injector 100 where a smaller amount of drug product is located in syringe barrel 112. Thus, the number of unique components is reduced and variation management is simplified. Threaded plunger rod 131 may also be adjustably installed to various depths as needed during the manufacturing and / or assembly process.
[0022] The audible indicator 140 is operably coupled to the drive assembly 120. In this example, the audible indicator 140 is in the form of a ring that at least partially surrounds the plunger rod guide 126, and in particular surrounds the rod portion 127 of the plunger rod guide 126. The audible indicator 140 includes an engagement portion 144 surrounded by one or more wing portions 142 that define the ring. The audible indicator 140 may be made of any number of materials, such as, for example, a polymer, such as a silicone polymer, a metallic material, a composite material, etc. In the illustrated example, the audible indicator 140 is made of a resilient material that allows the audible indicator 140 to expand or stretch radially.
[0023] The engagement portion 144 of the audible indicator 140 is in the form of a block or tab. When the audible indicator 140 is installed (i.e., when the wing portion 142 surrounds the rod portion 127 of the plunger rod guide 126), the engagement portion 144 is inserted into the slot 129 of the plunger rod guide 126. Thus, the audible indicator 140 is at least partially retained by the plunger rod guide 126.
[0024] When the engagement portion 144 of the audible indicator 140 is inserted into the slot 129 of the plunger rod guide 126, the engagement portion 144 engages and / or fits snugly against a portion of the plunger rod 131. In some examples, when the device 100 is in this initial or loaded state (i.e., prior to administration of the medicament 113), the engagement portion 144 of the audible indicator 140 may fit snugly within or abut against the second detent 135 of the plunger rod 131. In this configuration, the audible indicator 140 is in a generally relaxed state and is minimally stressed.
[0025] Generally, to actuate the device, the user presses the device 100 against the skin, causing the trigger ring 124 to disengage from the nut 122 and / or the plunger rod guide 126. Such disengagement allows the plunger rod guide 126 to rotate relative to the trigger ring 124. Because the torque spring 136 is in a wound or compressed state, the torque spring 136 begins to unwind, thereby rotating the plunger rod guide 126. The threaded connection between the plunger rod 131 and the nut 122 advances the plunger rod 131 and the plunger 133 toward the proximal end 102a of the housing 102, thereby inserting the needle or cannula 114 and administering the medicament 113. As a non-limiting example, U.S. Provisional Patent Application No. 62 / 719,367, filed August 17, 2018, describes the operating steps and components of the drive assembly in further detail and is therefore incorporated herein by reference in its entirety.
[0026] 2a and 2b, the delivery of the medicament 113 begins. It should be understood that for clarity, some components of the device 100 are not shown in FIG. 2a and 2b. During administration of the medicament 113, the plunger rod 131 moves axially relative to the plunger rod guide 120 and the audible indicator 140. Within a short travel distance of the plunger rod 131, due to an increase in the overall diameter of the plunger rod 131, the threaded portion 131a begins to push outward (i.e., radially) against the engagement portion 144 of the audible indicator 140. In some examples, the engagement portion 144 includes a chamfered or angled surface 144a that corresponds to the chamfered or angled surface 135a of the second detent 135 to aid in a smooth outward displacement by the audible indicator 140. In this position, the audible indicator 140 is in a stressed or stretched configuration during administration of the medicament 113. Specifically, the wing portions 142 remain coupled to the plunger rod guide 126 but are stretched to an outward configuration relative to the initial stressed configuration. Thus, the audible indicator 140 stores energy as the plunger rod 131 moves from the initial position toward the second position.
[0027] 3a and 3b, delivery of the medicament 113 is complete and the drive assembly 120, specifically the plunger rod 131, is in a second position resulting in the expulsion of the medicament 113 from the syringe 112. When the plunger rod 131 moves to this second position, the first detent 134 allows the audible indicator 140 to return to its original state and / or position. The engagement portion 144 of the audible indicator 140 engages the first detent 134 of the plunger rod 131, and the energy stored in the audible indicator 140 causes the engagement portion 144 (and in some instances a portion of the wing portion 142) to return to its original state and contact the plunger rod 131, producing an audible sound, such as a click.
[0028] In any mechanism that requires a force release, it is important to consider when the mechanism is subjected to force (i.e., when the mechanism is loaded) and how the force is applied to the mechanism. The audible indicator 140 described herein is not under load when the device 100 is not in use. Therefore, there is no longer a need to consider loose parts. During the initial actuation of the device, the torque spring 136 has a maximum force and a minimum amount of resistance. The audible indicator 140 is subjected to load during this initial actuation, which is when the device 100 is least affected by the load.
[0029] 4, plunger rod guide 126 may additionally include guide feature 128a in the form of a tab or key that engages keyhole 145 of the audible indicator to guide radial movement of engagement portion 144 of audible indicator 140. Additionally, guide feature 128 ensures that audible indicator 140 is properly oriented within device 100. This helps identify assembly errors in production since the part cannot be installed incorrectly.
[0030] As mentioned above, the audible indicator 140 may be made from many materials. In some examples, the audible indicator 140 is made from silicone (e.g., POM+Si / KEP-TS25H) to reduce friction between the audible indicator 140 and the plunger rod 131. In addition, as illustrated in FIG. 5, during dispensing, the audible indicator 140 slides over the threaded portion 131a of the plunger rod 131. To ensure that the user does not perceive the audible indicator 140 sliding over the threaded portion 131a during use of the device 100, the height of the engagement portion 144 of the audible indicator across the threads (illustrated as C1 in FIG. 5) should be equal to or greater than the distance between the threads ("P1") to ensure that the engagement portion 144 presses against more than one thread, thereby reducing the relative wobble that the user may experience. In particular, the chamfered surface 144 a of the engagement portion 144 also slides smoothly across the threaded portion 131 a of the plunger rod 131 .
[0031] It should be appreciated that in some examples, when the device 100 is in a loaded state, the audible indicator 140 may be in a partially stressed and / or stretched configuration. However, as the plunger rod 131 moves toward the second position, the plunger rod 131 exerts an additional outward or radial force on the audible indicator 140, causing the audible indicator 140 to return to a relaxed state at the engagement portion 144 of the audible indicator 140 when the engagement portion 144 moves from the threaded portion 131a of the plunger rod 131 to the first detent 134. Furthermore, it should be appreciated that in some examples, the plunger rod 131 may not include a second detent, so that the audible indicator 140 may simply remain in the stressed or stretched configuration until the engagement portion 144 of the audible indicator 140 enters the first detent 134.
[0032] In some aspects, the volume and tone of the audible sound may be adjusted by modifying the amount of force released, the relative geometry of the components, and / or the degrees of freedom of the vibrating and / or sound-producing components.
[0033] In some examples, the audible indicator may take different forms. Thus, Figures 6a and 6b illustrate an alternative audible indicator 240 for drug delivery device 200. It should be understood that device 200 may include similar and / or identical components to device 100, and therefore, for the sake of brevity, these features are not shown and described. In this example, the first end 231c of plunger rod guide 231 includes a magnetic member 231d. In this example, the audible indicator 240 is in the form of a metallic joint having a resilient member 242 and a metallic member 244. As illustrated in Figure 6a, in the loaded configuration, the metallic member 244 is positioned away from the plunger rod 231. As illustrated in Figure 6b, upon completion of administration of the drug, the magnetic force between the magnetic member 231d and the metallic member 244 causes the resilient member 242 to swing inward toward the plunger rod 231. Thus, the metallic member 244 engages the magnetic member 231d, thereby generating an audible sound. It should be appreciated that in some examples, the magnetic member may be coupled to an audible indicator and the first end 231c of the plunger rod 231 may include a metallic member.
[0034] In some examples, the audible indicator may be integrally formed with and / or coupled to other components of the device. Thus, Figures 7a-7d illustrate an alternative audible indicator 340 for drug delivery device 300. It should be understood that device 300 may include similar and / or identical components to device 100, and therefore, for the sake of brevity, these features are not shown and described. In this example, the audible indicator 340 is an integral component of trigger ring 324 and is in the form of a finger or hook that protrudes from trigger ring 324. Plunger rod 331 includes a detent or notch 335 that is dimensioned to accommodate the audible indicator 340.
[0035] In the initial configuration or position, as illustrated in Figures 7a and 7b, the audible indicator 340 is at least partially disposed within the detent 335 and is therefore in a relaxed configuration. In Figures 7c and 7d, the device 300 is actuated and relative movement begins to occur. First, the trigger ring 324 and / or the plunger rod 331 rotate relative to each other, which causes the audible indicator 340 to also rotate and move out of the detent 335 and abut the plunger rod 331, thus spreading the audible indicator 340 outward and applying a force to the audible indicator 340. Additionally, the relative axial movement of the trigger ring 324 and the plunger rod 331 along the longitudinal axis L occurs in the same manner as in the device 100 previously described in Figures 1a-3b. At the end of the dose, the audible indicator 340 does not engage an additional detent or notch, but rather abuts the second end 331c of the plunger rod 331 with a snap or click sound.
[0036] In some examples, the audible indicator may be integrally formed with and / or coupled to further components of the device. Thus, Figures 8a-8c illustrate an alternative audible indicator 440 for drug delivery device 400. It should be understood that device 400 may include similar / or identical components to devices 100, 200 and 300, and therefore, for the sake of brevity, these features are not shown and described. In this example, the audible indicator 440 is an integral component of plunger rod 431 and is in the form of any number of fingers or hooks protruding from second end 431c of plunger rod 431. In this example, plunger rod guide 426 includes at least a first opening or window 429a and a second opening or window 429b dimensioned to accommodate the audible indicator 440.
[0037] In an initial configuration or position, as illustrated in FIG. 8a, the audible indicator 440 is at least partially disposed within the first opening or window 429a and is therefore in a relaxed configuration. Upon actuation of the device 400, relative axial movement along the longitudinal axis L occurs between the plunger rod guide 426 and the plunger rod 431, displacing the audible indicator 440 from the first opening or window 429a and expanding inwardly, and applying a force to the audible indicator 440 by contact with the inner surface 429c of the plunger rod guide 426. At the end of dosing, the audible indicator 440 engages the second opening or window 429b and abuts the plunger rod guide 426 with a snap or click, thereby generating an audible sound.
[0038] As illustrated in FIG. 8b, in some approaches, the plunger rod guide 426 may include any number of additional first windows 429a to allow the plunger rod 431 to be positioned at different positions depending on the amount of drug being delivered. As illustrated in FIG. 8c, in some approaches, the plunger rod guide 426 may include an elongated first window 429a to accommodate positioning of the plunger rod 431 at any number of lengths along the longitudinal axis. The elongated first window 429a illustrated in FIG. 8c advantageously allows the audible indicator 440 to remain in a relaxed configuration during a significant amount of longitudinal movement during dosing, and to be loaded only immediately prior to the end of dosing. Other examples are possible.
[0039] In some approaches, the audible indicator may be integrally formed with and / or coupled to other components of the device. Thus, Figures 9a-9d illustrate an alternative audible indicator 540 for drug delivery device 500. It should be understood that device 500 may include similar and / or identical components to devices 100, 200, 300 and 400, and therefore, for the sake of brevity, these features are not shown and described. In this example, the audible indicator 540 is an integral component of plunger rod guide 526 and is in the form of any number of fingers or hooks that project inwardly from plunger rod guide 526. In this example, plunger rod 531 includes at least a first notch or detent 534 and a second notch or detent 535 that are dimensioned to accommodate the audible indicator 540.
[0040] In an initial configuration or position, as shown in Figures 9a and 9b, the audible indicator 540 is at least partially disposed within the first detent 534 and is therefore in a relaxed configuration. Upon actuation of the device 500, as shown in Figure 9c, relative axial movement along the longitudinal axis L occurs between the plunger rod guide 526 and the plunger rod 531, displacing the audible indicator 540 from the first detent 534 and spreading outwardly, and applying a force to the audible indicator 540 by contact with the plunger rod 531. At the end of dosing, as shown in Figure 9d, the audible indicator 540 engages the second detent 535 and abuts the plunger rod 531 with a snap or click, thereby generating an audible sound.
[0041] In Fig. 10a-d, an alternative audible indicator 640 for drug delivery device 600 is provided. It should be understood that device 600 may include similar and / or identical components to devices 100, 200, 300, 400 and 500, and therefore, for the sake of brevity, these features are not shown and described. In this example, audible indicator 640 is in the form of a resilient finger 642 that couples to second end 631c of plunger rod 631 using any number of techniques. Finger 642 is inserted into groove 628 (best shown in Fig. 10b) formed in plunger rod guide 626, thereby allowing finger 642 to axially traverse plunger rod guide 626 along longitudinal axis L. Plunger rod guide 626 further defines protrusion 629 having first surface 629a and second surface 629b. Protrusion 629 is disposed within groove 628.
[0042] As shown in Fig. 10c, during administration of the medication, the finger 642 engages the first surface 629a of the protrusion and displaces upwardly as a force is applied. At the end of administration, as shown in Fig. 10d, the finger 642 disengages from the first surface 629a of the protrusion 629 and abuts the second surface 629b of the protrusion 629 with a slap or click, generating an audible sound.
[0043] 11a-11b, an alternative audible indicator 740 for drug delivery device 700 is provided. It should be understood that device 700 may include similar and / or identical components to devices 100, 200, 300, 400, 500 and 600, and therefore, for the sake of brevity, these features are not shown and described. In this example, the audible indicator 740 is in the form of a spring having a contact arm 742. The plunger rod guide 726 includes a wing-like portion 728 for receiving a first portion 740a of the spring 740. In these examples, the audible indicator 740 is located within the wing-like portion 728 and comfortably positioned radially inward. Although not shown, the audible indicator 740 may be positioned through an opening, slot, and / or notch formed in the plunger rod guide 726 to allow the contact arm 742 to contact the plunger rod 731. When the plunger rod 731 is disposed within the plunger rod guide 726, the plunger rod 731 displaces the contact arm 742 outward, thereby exerting a force on the audible indicator 740. As shown in FIG. 11b, at the end of dosing, the contact arm 742 of the audible indicator 740 disengages from the plunger rod 731, generating an audible vibration. In some examples, the contact arm 742 of the audible indicator 740 may contact the inner surface 726a of the plunger rod guide 726, generating a slap or click sound.
[0044] Advantageously, the described audible indicator clearly indicates when the user can safely remove the device from the injection site. The audible indicator is activated by displacing the axial position of the plunger rod, thereby ensuring that the audible sound is not generated prematurely, but rather only when the plunger rod has moved a predetermined distance that represents the end of drug administration. This mechanism generates the sound using minimal additional parts, and the design can ensure accurate assembly by only allowing one way of attachment. In some examples, the first detent or portion that the audible indicator engages may not be located at the end of the plunger rod. Rather, this detent or notch may be located at any distance along the plunger rod that represents the end of drug administration.
[0045] In the above description, various assemblies, devices, and methods for use with drug delivery devices are described. It should be clarified that the assemblies, drug delivery devices, or methods can further include the use of the drugs described below, and it should be noted that the following list should not be considered as all-inclusive or limiting. The drugs are contained in a reservoir. In some examples, the reservoir is a primary container that is filled or pre-filled for treatment with the drug. The primary container can be a cartridge or a pre-filled syringe.
[0046] For example, the drug delivery device, or more specifically the reservoir of the device, may be loaded with a colony stimulating factor, such as granulocyte colony stimulating factor (G-CSF). Such G-CSF agents include, but are not limited to, Neupogen® (filgrastim) and Neulasta® (pegfilgrastim). In various other embodiments, the drug delivery device may be used with various pharmaceutical agents, such as erythropoietin stimulating agents (ESAs), which may be in liquid or lyophilized form.ESAs include Epogen® (epoetin alfa), Aranesp® (darbepoetin alfa), Dynepo® (epoetin delta), Mircera® (methyoxypolyethylene glycol epoetin beta), Hematide®, MRK-2578, INS-22, Retacrit® (epoetin zeta), Neorecormon® (epoetin beta), Sil apo® (epoetin zeta), Binocrit® (epoetin alfa), epoetin alfa Hexal, Abseamed® (epoetin alfa), Ratioepo® (epoetin theta), Eporatio® (epoetin theta), Biopoin® (epoetin theta), epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, and epoetin de and any molecule that stimulates red blood cell production, such as erythrocytes, as well as the molecules described in U.S. Pat. Nos. 4,703,008, 5,441,868, 5,547,933, 5,618,698, 5,621,080, 5,756,349, 5,767,078, 5,773,569, 5,955,422, and 5,986,047, each of which is incorporated by reference in its entirety. The molecule is a molecule or a variant or analog thereof as disclosed in PCT International Publication Nos. 6,583,272, 7,084,245, and 7,271,689, and in PCT Publication Nos. WO 91 / 05867, WO 95 / 05465, WO 96 / 40772, WO 00 / 24893, WO 01 / 81405, and WO 2007 / 136752.
[0047] The ESA can be an erythropoiesis stimulating protein. As used herein, "erythropoiesis stimulating protein" refers to any protein that directly or indirectly activates the erythropoietin receptor, for example, by binding to the receptor and causing dimerization. Erythropoiesis stimulating proteins include erythropoietin and its variants, analogs, or derivatives that bind to and activate the erythropoietin receptor, antibodies that bind to and activate the erythropoietin receptor, or peptides that bind to and activate the erythropoietin receptor. Erythropoiesis stimulating proteins include, but are not limited to, epoetin alpha, epoetin beta, epoetin delta, epoetin omega, epoetin iota, epoetin zeta, and analogs thereof, PEGylated erythropoietin, carbamylated erythropoietin, mimetic peptides (including EMP1 / hematide), and mimetic antibodies. Exemplary erythropoiesis stimulating proteins include erythropoietin, darbepoietin, erythropoietin agonist variants, and peptides or antibodies that bind to and activate the erythropoietin receptor (and include compounds reported in U.S. Patent Application Publication Nos. 2003 / 0215444 and 2006 / 0040858, the disclosures of each of which are incorporated by reference in their entireties), as well as those described in U.S. Patent Application Publication Nos. 4,703,008; 5,441,868; 5,547,933; 5,618,698; 5,703,102; and 5,712,136, each of which are incorporated by reference in their entireties. Specification No. 621,080, Specification No. 5,756,349, Specification No. 5,767,078, Specification No. 5,773,569, Specification No. 5,955,422 Specification No. 5,830,851, Specification No. 5,856,298, Specification No. 5,986,047, Specification No. 6,030,086, Specification No. 6 ,310,078, 6,391,633, 6,583,272, 6,586,398, 6,900,292, 6,750,369, 7,030,226, 7,084,245; and 7,217,689;U.S. Patent Application Publication Nos. 2002 / 0155998, 2003 / 0077753, 2003 / 0082749, 2003 / 0143202, 2004 / 0009902, 2004 / 0071694, 2004 / 0091961, 2004 / 0143857, and 2004 / 0157293 Specification, 2004 / 0175379, 2004 / 0175824, 2004 / 0229318, 2004 / 0248815, 200 Specification No. 4 / 0266690, Specification No. 2005 / 0019914, Specification No. 2005 / 0026834, Specification No. 2005 / 0096461, Specification No. 2005 / 0107297 Specifications, 2005 / 0107591, 2005 / 0124045, 2005 / 0124564, 2005 / 0137329, 2005 / Specification No. 0142642, Specification No. 2005 / 0143292, Specification No. 2005 / 0153879, Specification No. 2005 / 0158822, Specification No. 2005 / 0158832 , 2005 / 0170457, 2005 / 0181359, 2005 / 0181482, 2005 / 0192211, 2005 / 0202538, 2005 / 0227289, 2005 / 0244409, 2006 / 0088906; and 2006 / 0111279;and PCT International Publication Nos. 91 / 05867, 95 / 05465, 99 / 66054, 00 / 24893, 01 / 81405, 00 / 61637, 01 / 36489, 02 / 014356, 02 / 19963, 02 / 20034, 02 / 49673, 02 / 085940 and 03 / 029291. Brochure No. 2003 / 055526, Brochure No. 2003 / 084477, Brochure No. 2003 / 094858, Brochure No. 2004 / 002417, Brochure No. 2004 / 002424, Brochure No. 2004 / 009627, Brochure No. 2004 / 024761, Brochure No. 2004 / 033651, Brochure No. 2004 / 035603, Brochure No. 2004 / 043382, Brochure No. 2004 / 101600, Brochure No. 2004 / 101606, Brochure No. 2004 / 101611, Brochure No. 2004 / 106373, Brochure No. 2004 / 018667, Brochure No. 2005 / 001025, Brochure No. 2005 / 001136, Brochure No. 2005 / 021579, Brochure No. 2005 / 025606, Brochure No. 2005 / 032460, Brochure No. 2005 / 051327, Brochure No. 2005 / 063808, Brochure No. 2005 / 063 erythropoietin molecules or variants or analogs thereof as disclosed in US Pat. Nos. 2005 / 809, 2005 / 070451, 2005 / 081687, 2005 / 084711, 2005 / 103076, 2005 / 100403, 2005 / 092369, 2006 / 50959, 2006 / 02646; and 2006 / 29094.
[0048] Examples of other pharmaceuticals for use with the device may include, but are not limited to, antibodies such as Vectibix® (panitumumab), Xgeva™ (denosumab) and Prolia™ (denosumab); other biologics such as Enbrel® (etanercept, TNF receptor / Fc fusion protein, TNF blocker), Neulasta® (pegfilgrastim, PEGylated filgastriam, PEGylated G-CSF, PEGylated hu-Met-G-CSF), Neupogen® (filgrastim, G-CSF, hu-MetG-CSF), and Nplate® (romiplostim); small molecule drugs such as Sensipar® (cinacalcet). The device may also be used with therapeutic antibodies, polypeptides, proteins, or other chemicals such as iron, e.g., ferumoxytol, iron dextran, ferric gluconate, and ferric oxide. The pharmaceutical agent may be in liquid form or may be reconstituted with water from a lyophilized form.
[0049] Among certain exemplary proteins are the specific proteins described below, including fusions, fragments, analogs, variants, or derivatives thereof.
[0050] As disclosed in PCT Publication WO 03 / 002713, each of which is individually and specifically incorporated herein by reference in its entirety in its entirety, includes OPGL-specific antibodies having either a light chain of SEQ ID NO:2 as set forth in Figure 2 of said publication and / or a heavy chain of SEQ ID NO:4 as set forth in Figure 4 of said publication, and with regard to OPGL-specific antibodies and antibody related proteins, in particular OPGL-specific antibodies (also referred to as RANKL-specific antibodies, peptibodies, etc.), peptibodies, and related proteins, including fully humanized and human OPGL-specific antibodies, in particular fully humanized monoclonal antibodies, including, but not limited to, the antibodies described in said publications, each of which is individually and specifically incorporated herein by reference in its entirety in its entirety, including, but not limited to, those antibodies having the sequences described in said publications and shown in said publications, i.e., 9H7, 18B2, 2D8, 2E11, 16E1, and 22B3.
[0051] TN8-19-1 through TN8-19-40, TN8-19 con1, and TN8-19 con2, each of which is individually and specifically incorporated herein by reference in its entirety as disclosed in U.S. Patent Application Publication No. 2004 / 0181033 and PCT Publication No. WO 2004 / 058988. Myostatin binding proteins, peptibodies, and related proteins including, but not limited to, the mTN8-19 family of peptibodies, including those in SEQ ID NOs: 305-351, including con2, the mL2 family of SEQ ID NOs: 357-383, the mL15 family of SEQ ID NOs: 384-409, the mL17 family of SEQ ID NOs: 410-438, the mL20 family of SEQ ID NOs: 439-446, the mL21 family of SEQ ID NOs: 447-452, the mL24 family of SEQ ID NOs: 453-454, and the peptibodies in SEQ ID NOs: 615-631, particularly including myostatin-specific peptibodies described in the above publications, which are incorporated by reference in their entirety herein with particular reference in part to myostatin-specific peptibodies.
[0052] IL-4 receptor specific antibodies as disclosed in PCT Publication No. WO 2005 / 047331, i.e., PCT International Application No. PCT / US2004 / 37242 and U.S. Patent Application Publication No. 2005 / 112694, each of which is individually and specifically incorporated herein by reference in its entirety, particularly antibodies as described in the above publications, particularly, but not limited to, those shown in the above publications, i.e., L1H1, L1H2, L1H3, L1H4, L1H5, L1H6, L1H7, L1H8, L1H9, L1H1H, L1H2H, L1H3H, L1H4H, L1H5H, L1H6H, L1H7H, L1H8H, L1H9H ... , L1H10, L1H11, L2H1, L2H2, L2H3, L2H4, L2H5, L2H6, L2H7, L2H8, L2H9, L2H10, L2H11, L2H12, L2H13, L2H14, L3H1, L4H1, L5H1, L6H1, and the like, which are incorporated by reference in their entireties herein with particular reference in part to IL-4 receptor specific antibodies, peptibodies, and related proteins, particularly those which inhibit effects mediated by binding of IL-4 and / or IL-13 to the receptor.
[0053] IL1-R1 specific binding proteins, particularly monoclonal antibodies, in particular interleukin 1-receptor 1 ("IL1-R1") specific antibodies, peptibodies, and related proteins, including, but not limited to, those set forth in the above publication, i.e., 15CA, 26F5, 27F2, 24E12, and 10H7, each of which is individually and specifically incorporated by reference in its entirety in its entirety, as disclosed in U.S. Patent Application Publication No. 2004 / 097712, each of which is individually and specifically incorporated by reference in its entirety in its entirety, and which are herein incorporated by reference in their entirety ...
[0054] The sequences of the following publications, each of which is individually and specifically incorporated herein by reference in its entirety as disclosed in the following publications, in particular those sequences described in the following publications: L1(N), L1(N)WT, L1(N)1K WT, 2xL1(N), 2xL1(N)WT, Con4(N), Con4(N)1K WT, 2xCon4(N)1K, L1C, L1C 1K, 2xL1C, Con4C, Con4C 1K, 2xCon4C and, in particular with respect to Ang2 specific antibodies and peptibodies, including, but not limited to, those described in PCT Publication No. WO 03 / 057134 and U.S. Patent Application Publication No. 2003 / 0229023, each of which is incorporated by reference in its entirety herein, and with respect to anti-Ang2 antibodies and formulations, in particular the various permutations of Ab526, Ab528, Ab531, Ab541, Ab542, Ab543, Ab544, Ab545, Ab546, Ab547, Ab548, Ab549 ... , Ab533, Ab535, Ab536, Ab537, Ab540, Ab543, Ab544, Ab545, Ab546, A551, Ab553, Ab555, Ab558, Ab559, Ab565, AbF1AbFD, AbFE, AbFJ, AbFK, AbG1D4, AbGC1E8, AbH1C12, AblA1, AblF, AblK, AblP, and Ang2 specific antibodies, peptibodies, and related proteins, including anti-Ang2 antibodies and formulations such as those described in PCT Publication WO 2003 / 030833, the entirety of which is incorporated by reference herein with respect to AblP.
[0055] NGF-specific antibodies, peptibodies, and related proteins, including but not limited to those described in U.S. Patent Application Publication No. 2005 / 0074821 and U.S. Patent No. 6,919,426, each of which is individually and specifically incorporated herein by reference in its entirety as disclosed therein, particularly including but not limited to the NGF-specific antibodies set forth in the above publications, i.e., 4D4, 4G6, 6H9, 7H2, 14D10, and 14D11, each of which is individually and specifically incorporated herein by reference in its entirety as disclosed therein, particularly including but not limited to the NGF-specific antibodies and related proteins thereof.
[0056] For example, CD22-specific antibodies, peptibodies, and related proteins, such as those described in U.S. Pat. No. 5,789,554, the entirety of which is incorporated herein by reference with respect to CD22-specific antibodies and related proteins, including, but not limited to, humanized and fully human monoclonal antibodies, including, but not limited to, particularly human CD22-specific IgG antibodies, such as, for example, a dimer of human-mouse monoclonal hLL2 gamma chain disulfide linked to a human-mouse monoclonal hLL2 kappa chain, including, but not limited to, the human CD22-specific fully humanized antibody of epratuzumab (CAS Registry No. 501423-23-0).
[0057] The IGF-1 specific antibodies shown in PCT Publication WO 06 / 069202, each of which is individually and specifically incorporated herein by reference in its entirety as disclosed therein, namely, L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H28, L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H30, L41H30, L42H30, L43H30, L44H30, L45H30, L46H30, L47H30, L48H30, L49 ...9H30, L49H30, L49H30, L49H30, L49H30, L49H30, L49H30, L49H30, L49H3 and IGF-1 receptor specific antibodies, peptibodies, and related proteins, such as those described in the above publications, which are incorporated by reference in their entireties with respect to IGF-1 receptor specific antibodies and related proteins, including, but not limited to, 31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50H50, L51H51, L52H52, and IGF-1 R-binding fragments and derivatives thereof.
[0058] Also among the non-limiting examples of anti-IGF-1R antibodies for use in the methods and compositions of the invention are each and every one of those described below. (i) Antibodies described in U.S. Patent Application Publication Nos. 2006 / 0040358 (published February 23, 2006), 2005 / 0008642 (published January 13, 2005), and 2004 / 0228859 (published November 18, 2004), including, but not limited to, Antibody 1A (DSMZ Deposit No. DSM ACC 2586), Antibody 8 (DSMZ Deposit No. DSM ACC 2589), Antibody 23 (DSMZ Deposit No. DSM ACC 2588), and Antibody 18. (ii) including, but not limited to, antibodies 2F8, A12, and IMC-A12, described in PCT Publication Nos. WO 06 / 138729 (published December 28, 2006) and WO 05 / 016970 (published February 24, 2005), and Lu et al. (2004), J. Biol. Chem. 279:2856-2865. (iii) PCT International Publication Nos. 07 / 012614 (published on February 1, 2007), 07 / 000328 (published on January 4, 2007), 06 / 013472 (published on February 9, 2006), 05 / 058967 (published on June 30, 2005), and 03 / 059951 (published on July 24, 2003). (iv) including, but not limited to, antibody 7C10, chimeric antibody C7C10, antibody h7C10, antibody 7H2M, chimeric antibody *7C10, antibody GM607, humanized antibody 7C10 version 1, humanized antibody 7C10 version 2, humanized antibody 7C10 version 3, and antibody 7H2HM, as described in U.S. Patent Application Publication No. 2005 / 0084906 (published April 21, 2005). (v) including, but not limited to, antibodies EM164, resurfaced EM164, humanized EM164, huEM164 v1.0, huEM164 v1.1, huEM164 v1.2, and huEM164 v1.3, as described in U.S. Patent Application Publication Nos. 2005 / 0249728 (published November 10, 2005), 2005 / 0186203 (published August 25, 2005), 2004 / 0265307 (published December 30, 2004), and 2003 / 0235582 (published December 25, 2003), and Maloney et al. (2003), Cancer Res. 63:5073-5083. (vi) each of the antibodies produced by hybridomas having ATCC Accession Nos. PTA-2792, PTA-2788, PTA-2790, PTA-2791, PTA-2789, PTA-2793, and antibodies 2.12.1, 2.13.2, 2.14.3, 3.1.1, 4.9.2, and 4.17.3, as described in U.S. Pat. Nos. 7,037,498 (issued May 2, 2006), 2005 / 0244408 (published November 30, 2005), and 2004 / 0086503 (published May 6, 2004), and Cohen, et al. (2005), Clinical Cancer Res. 11:2063-2073, e.g., antibody CP-751,871. (vii) including, but not limited to, antibody 19D12, as described in U.S. Patent Application Publication Nos. 2005 / 0136063 (published June 23, 2005) and 2004 / 0018191 (published January 29, 2004), and an antibody comprising a heavy chain encoded by a polynucleotide in plasmid 15H12 / 19D12HCA(γ4), deposited with the ATCC under serial no. PTA-5214, and a light chain encoded by a polynucleotide in plasmid 15H12 / 19D12LCF(κ), deposited with the ATCC under serial no. PTA-5220. (viii) With respect to the foregoing antibodies, peptibodies, and related proteins specifically targeting the IGF-1 receptor, including, but not limited to, the antibodies PINT-6A1, PINT-7A2, PINT-7A4, PINT-7A5, PINT-7A6, PINT-8A1, PINT-9A2, PINT-11A1, PINT-11A2, PINT-11A3, PINT-11A4, PINT-11A5, PINT-11A7, PINT-11A12, PINT-12A1, PINT-12A2, PINT-12A3, PINT-12A4, and PINT-12A5, each of which is incorporated by reference in its entirety herein.
[0059] B-7 related protein 1 specific antibodies, peptibodies, related proteins and the like ("B7RP-1", also referred to in the literature as B7H2, ICOSL, B7h, and CD275), in particular B7RP specific fully human monoclonal IgG2 antibodies, in particular fully human IgG2 monoclonal antibodies that bind to an epitope in the first immunoglobulin-like domain of B7RP-1, in particular those that inhibit the interaction of B7RP-1 with ICOS, the natural receptor for B7RP-1, in particular on activated T cells, in all of the above respects, in particular as disclosed in the following publications, each of which is individually and specifically incorporated herein by reference in its entirety: 16H (having therein the light chain variable sequence of SEQ ID NO:1 and the heavy chain variable sequence of SEQ ID NO:7), 5D (having therein the light chain variable sequence of SEQ ID NO:8), 6H (having therein the light chain variable sequence of SEQ ID NO:9), 7H (having therein the light chain variable sequence of SEQ ID NO:10), 8H (having therein the heavy chain variable sequence of SEQ ID NO:11), and 9H (having therein the light chain variable sequence of SEQ ID NO:12). and the heavy chain variable sequence of SEQ ID NO:9), 2H (having endothelial light chain variable sequence of SEQ ID NO:3 and heavy chain variable sequence of SEQ ID NO:10), 43H (having endothelial light chain variable sequence of SEQ ID NO:6 and heavy chain variable sequence of SEQ ID NO:14), 41H (having endothelial light chain variable sequence of SEQ ID NO:5 and heavy chain variable sequence of SEQ ID NO:13), and 15H (having endothelial light chain variable sequence of SEQ ID NO:4 and heavy chain variable sequence of SEQ ID NO:12) as disclosed in U.S. Patent Application Publication No. 2008 / 0166352 and PCT Publication No. WO 07 / 011941, the entireties of which are incorporated herein by reference with respect to such antibodies and related proteins, including, but not limited to, the antibodies set forth in the following publications:
[0060] For example, IL-15 specific antibodies, peptibodies, and related proteins, particularly antibodies, particularly humanized monoclonal antibodies, such as those disclosed in U.S. Patent Application Publication Nos. 2003 / 0138421, 2003 / 023586, and 2004 / 0071702, and U.S. Patent Application No. 7,153,507, each of which is incorporated herein by reference in its entirety for IL-15 specific antibodies and related proteins, including peptibodies, such as, for example, but not limited to, HuMax IL-15 antibody and related proteins, such as 146B7.
[0061] IFN gamma specific antibodies, peptibodies, and related proteins, etc., particularly human IFN gamma specific antibodies, in particular fully human anti-IFN gamma antibodies, such as, for example, the antibodies set forth in US Patent Application Publication No. 2005 / 0004353, i.e., 1118, 1118*, 1119, 1121, and 1121*, which are incorporated herein by reference in their entirety. The entire sequences of the heavy and light chains of each of these antibodies, as well as the sequences of their heavy and light chain variable regions and complementarity determining regions, are each individually and specifically incorporated herein by reference in their entirety as disclosed in the aforementioned publications and in Thakur et al. (1999), Mol. Immunol. 36:1107-1115. In addition, the description of the properties of these antibodies provided in the aforementioned publications is also incorporated herein by reference in their entirety. As disclosed in the above publications, specific antibodies include those having a heavy chain of SEQ ID NO: 17 and a light chain of SEQ ID NO: 18, those having a heavy chain variable region of SEQ ID NO: 6 and a light chain variable region of SEQ ID NO: 8, those having a heavy chain of SEQ ID NO: 19 and a light chain of SEQ ID NO: 20, those having a heavy chain variable region of SEQ ID NO: 10 and a light chain variable region of SEQ ID NO: 12, those having a heavy chain of SEQ ID NO: 32 and a light chain of SEQ ID NO: 20, those having a heavy chain variable region of SEQ ID NO: 30 and a light chain variable region of SEQ ID NO: 12, those having a heavy chain sequence of SEQ ID NO: 21 and a light chain sequence of SEQ ID NO: 22, those having a heavy chain variable region of SEQ ID NO: 14 and a light chain variable region of SEQ ID NO: 16, those having a heavy chain of SEQ ID NO: 21 and a light chain of SEQ ID NO: 33, and those having a heavy chain variable region of SEQ ID NO: 14 and a light chain variable region of SEQ ID NO: 31. The specific antibody contemplated is antibody 1119 as disclosed in the aforementioned U.S. Patent Application Publication, which has the complete heavy chain of SEQ ID NO:17 as disclosed in said publication, and the complete light chain of SEQ ID NO:18 as disclosed in said publication.
[0062] As disclosed in U.S. Patent Application Publication No. 2003 / 0195156 and U.S. Patent Application Publication No. 2006 / 0135431, each of which is individually and specifically incorporated herein by reference in its entirety, TALL-1 specific antibodies, peptibodies, and related proteins such as those described in the above publications, each of which is incorporated herein by reference in its entirety in its entirety, particularly with respect to the TALL-1 binding proteins, molecules in Tables 4 and 5B, as well as other TALL specific binding proteins.
[0063] Parathyroid hormone ("PTH")-specific antibodies, peptibodies, and related proteins, such as those described in U.S. Pat. No. 6,756,480, which is incorporated by reference in its entirety herein with particular reference in part to proteins that bind PTH.
[0064] Thrombopoietin receptor ("TPO-R")-specific antibodies, peptibodies, and related proteins, such as those described in U.S. Pat. No. 6,835,809, which is incorporated by reference in its entirety herein with particular reference in part to proteins that bind to TPO-R.
[0065] Hepatocyte growth factor ("HGF") specific antibodies, peptibodies, and related proteins, including those that target HGF / SF; the cMet axis (HGF / SF:c-Met), such as fully human monoclonal antibodies that neutralize hepatocyte growth factor / scatter (HGF / SF), described in U.S. Patent Application Publication No. 2005 / 0118643 and PCT Publication No. WO 2005 / 017107, huL2G7, described in U.S. Patent No. 7,220,410, and OA-5d5, described in U.S. Patent Nos. 5,686,292 and 6,468,529, and PCT Publication No. WO 96 / 38557, each of which is incorporated by reference in its entirety with particular reference in part to proteins that bind HGF.
[0066] TRAIL-R2 specific antibodies, peptibodies, related proteins, and the like, such as those described in U.S. Pat. No. 7,521,048, which is incorporated by reference in its entirety herein with particular reference in part to proteins that bind TRAIL-R2.
[0067] Activin A-specific antibodies, peptibodies, related proteins, and the like, including, but not limited to, those described in U.S. Patent Application Publication No. 2009 / 0234106, the entirety of which is incorporated by reference herein, with particular reference in part to proteins that bind activin A.
[0068] Particularly relevant to proteins that bind TGF-β are TGF-β specific antibodies, peptibodies, related proteins, and the like, including, but not limited to, those described in U.S. Pat. No. 6,803,453 and U.S. Patent Application Publication No. 2007 / 0110747, each of which is incorporated by reference in its entirety herein.
[0069] Amyloid β protein specific antibodies, peptibodies, related proteins, etc., including but not limited to those described in PCT Publication WO 2006 / 081171, which is hereby incorporated by reference in its entirety with particular reference in part to proteins that bind to amyloid β protein. One contemplated antibody is an antibody having a heavy chain variable region comprising SEQ ID NO:8 and a light chain variable region having SEQ ID NO:6, as disclosed in the aforementioned publication.
[0070] c-Kit specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in U.S. Patent Application Publication No. 2007 / 0253951, which is hereby incorporated by reference in its entirety with particular reference in part to proteins that bind c-Kit and / or other stem cell factor receptors.
[0071] OX40L-specific antibodies, peptibodies, related proteins, and the like, including, but not limited to, those described in U.S. Patent Application Publication No. 2006 / 0002929, which is incorporated by reference in its entirety, with particular reference in part to proteins that bind OX40L and / or other ligands of the OX40 receptor; Activase® (alteplase, tPA), Aranesp® (darbepoetin), Epogen® (epoetin alfa, or erythropoietin), GLP-1, Avonex® (interferon beta 1a), Bexxar® (tositumomab, an anti-CD22 monoclonal antibody), Betaseron® (interferon-beta), Campath® (alemtuzumab, an anti-CD52 monoclonal antibody), Dynepo® (epoetin delta), Velcade® (bortezomib), MLN0002 (anti-alpha4beta7 mAb), MLN1202 (anti-CCR2 chemokine receptor mAb), Enbrel (etanercept, TNF-receptor / Fc fusion protein, TNF blocker), Eprex® (epoetin alfa), Erbitux® (cetuximab, anti-EGFR / HER1 / c-ErbB-1), Genotropin® (somatropin, human growth hormone), Herceptin® (trastuzumab, anti-HER2 / neu(erbB2) receptor mAb), Hu Matrope® (somatropin, human growth hormone), Humira® (adalimumab), insulin solution, Infergen® (interferon alfacon-1), Natrecor® (nesiritide, recombinant human B-type natriuretic peptide (hBNP), Kineret® (anakinra), Leukine® (sargamostim, rhuGM-CSF), LymphoCide® (epratuzumab, anti-CD22 mAb), Benlysta™ (lymphostat B, belimumab, anti-BlyS mAb), Metalyse® (tenecteplase, t-PA analog), Mircera® (methoxypolyethylene glycol epoetin beta), Mylotarg® (gemtuzumab ozogamicin), Raptiva® (efalizumab), Cimzia® (certolizumab pegol, CDP870), Soliris™ (eculizumab), pexelizumab (anti-C5 complement), Numax® (MEDI-524), Lucentis® (ranibizumab), Panorex® (17-1A, edrecolomab), Trabio® (lerdelimumab), TheraCim hR3 (nimotuzumab), Omnitarg (pertuzumab, 2C4), Osidem® (IDM-1), OvaRex® (B43.13), Nuvion® (vigilizumab), cantuzumab mertansine (huC242-DM1), NeoRecormon® (epoetin beta), Neumega® (oprelvekin, human interleukin-11), Neulasta® (PEGylated filgastrim, PEGylated G-CSF, PEGylated hu-Met-G-CSF), Neupogen® (filagrastim, G-CSF, hu-MetG-CSF), Orthoclone OKT3® (muromonab-CD3, anti-CD3 monoclonal antibody), Procrit® (epoetin alfa), Remicade® (infliximab, anti-TNFα monoclonal antibody), Reopro® (abciximab, anti-GP llb / llia receptor monoclonal antibody), Actemra® (anti-IL6 receptor mAb), Avastin® (bevacizumab), HuMax-CD4 (zanolimumab), Rituxan® (rituximab, anti-CD20 mAb), Tarceva® (erlotinib), Roferon-A®- (interferon alpha-2a), Simulect® (basiliximab), Prexige® (lumiracoxib), Synagis® (palivizumab), 146B7-CHO (anti-IL 15 antibody, see U.S. Pat. No. 7,153,507), Tysabri® (natalizumab, anti-α4 integrinmAb), Valortim® (MDX-1303, anti-B, anthrax protective antigen mAb), ABthrax™, Vectibix® (panitumumab), Xolair® (omalizumab), ETI211 (anti-MRSA mAb), IL-1 Trap (the Fc portion of human IgG1 and the extracellular domains of both IL-1 receptor components (type I receptor and receptor accessory protein)), VEGF Trap (the Ig domain of VEGFR1 fused to IgG1 Fc), Zenapax® (daclizumab), Zenapax® (daclizumab, anti-IL-2Rα mAb), Zevalin® (ibritumomab tiuxetan), Zetia® (ezetimibe), Orencia® (atacicept, TACI-Ig), anti-CD80 monoclonal antibody (galiximab), anti-CD23 mAb (lumiliximab), BR2-Fc (huBR3 / huFc fusion protein, soluble BAFF antagonist), CNTO 148 (golimumab, anti-TNFα mAb), HGS-ETR1 (mapatumumab, human anti-TRAIL receptor-1 mAb), HuMax-CD20 (ocrelizumab, anti-CD20 human mAb), HuMax-EGFR (zalutumumab), M200 (volociximab, anti-α5β1 integrin mAb), MDX-010 (ipilimumab, anti-CTLA-4 mAb and VEGFR-1 (IMC-18F1), anti-BR3 mAb, anti-C, difficile toxin A and toxin BC mAbs MDX-066 (CDA-1) and MDX-1388), anti-CD22 dsFv-PE38 conjugate (CAT-3888 and CAT-8015), anti-CD25 mAb (HuMax-TAC), anti-CD3 mAb (NI-0401), adecatumumab, anti-CD30 mAb (MDX-060), MDX-1333 (anti-IFNAR), anti-CD38 mAb (HuMax CD38), anti-CD40L mAb, anti-Cripto mAb, anti-CTGF idiopathic pulmonary fibrosis phase I fibrogen (FG-3019), anti-CTLA4 mAb, anti-eotaxin 1 mAb (CAT-213), anti-FGF8 mAb, anti-ganglioside GD2 mAb, anti-ganglioside GM2 mAbmAb, anti-GDF-8 human mAb (MYO-029), anti-GM-CSF receptor mAb (CAM-3001), anti-HepC mAb (HuMax HepC), anti-IFNα mAb (MEDI-545, MDX-1103), anti-IGF1R mAb, anti-IGF-1R mAb (HuMax-Inflam), anti-IL12 mAb (ABT-874), anti-IL 12 / IL23 mAb (CNTO 1275), anti-IL 13 mAb (CAT-354), anti-IL2Ra mAb (HuMax-TAC), anti-IL5 receptor mAb, anti-integrin receptor mAb (MDX-018, CNTO 95), anti-IP10 ulcerative colitis mAb (MDX-1100), anti-LLY antibody, BMS-66513, anti-mannose receptor / hCGβ mAb (MDX-1307), anti-mesothelin dsFv-PE38 conjugate (CAT-5001), anti-PD1 mAb (MDX-1106 (ONO-4538)), anti-PDGFRα antibody (IMC-3G3), anti-TGFβ mAb (GC-1008), anti-TRAIL receptor 2 human mAb (HGS-ETR2), anti-TWEAK mAb, anti-VEGFR / Flt-1 mAb, anti-ZP3 mAb (HuMax-ZP3), NVS antibody #1, and NVS antibody #2.
[0072] Sclerostin antibodies can also be included, such as, but not limited to, romosozumab, biosozumab, or BPS 804 (Novartis). Further therapeutic agents can be included, such as rilotumumab, bixalomer, trebananib, ganitumab, conatumumab, motesanib diphosphate, brodalumab, vidupiprant, panitumumab, denosumab, NPLATE, PROLIA, VECTIBIX, or XGEVA. Additionally, monoclonal antibodies (IgG) that bind to human proprotein convertase subtilisin / kexin type 9 (PCSK9) can be included in the device.Such PCSK9-specific antibodies include those described in the following patents or patent applications, each of which is incorporated herein by reference in its entirety for all purposes: U.S. Pat. No. 8,030,547, U.S. Patent Application Publication No. 2013 / 0064825, WO 2008 / 057457, WO 2008 / 057458, WO 2008 / 057459, WO 2008 / 057451, WO 2008 / 057452, WO 2008 / 057453, WO 2008 / 057454, WO 2008 / 057455, WO 2008 / 057456, WO 2008 / 057457, WO 2008 / 057458, WO 2008 / 057459 ... International Publication No. 08 / 063382, International Publication No. 2008 / 133647, International Publication No. 2009 / 100297, International Publication No. 2009 / 100318, International Publication No. 2011 / 037791, International Publication No. 2011 / 053759, International Publication No. 2011 / 053783, International Publication No. 2008 / 125623, International Publication International Publication No. 2011 / 072263, International Publication No. 2009 / 055783, International Publication No. 2012 / 0544438, International Publication No. 2010 / 029513, International Publication No. 2011 / 111007, International Publication No. 2010 / 077854, International Publication No. 2012 / 088313, International Publication No. 2012 / 101251, These include, but are not limited to, Repatha® (evolocumab) and Praluent® (alirocumab) and molecules, variants, analogues, or derivatives thereof disclosed in WO 2012 / 101252, WO 2012 / 101253, WO 2012 / 109530, and WO 2001 / 031007.
[0073] Oncolytic immunotherapeutic agents or other oncolytic HSVs for melanoma or other cancer treatments can also be included. Examples of oncolytic HSVs include, but are not limited to, oncolytic immunotherapeutic agents talimogene laherparepvec (US Pat. Nos. 7,223,593 and 7,537,924); OncoVEXGALV / CD (US Pat. No. 7,981,669); OrienX010 (Lei et al. (2013), World J. Gastroenterol., 19:5138-5143); G207,1716; NV1020; NV12023; NV1034 and NV1042 (Vargehes et al. (2002), Cancer Gene Ther., 9(12):967-978).
[0074] Also included are TIMPs. TIMPs are endogenous tissue inhibitors of metalloproteinase (TIMP) and are important in many natural processes. TIMP-3 is expressed by a variety of cells and is present in the extracellular matrix, inhibiting all major cartilage-degenerating metalloproteinases and may play a role in many degenerative diseases of connective tissue, including rheumatoid arthritis and osteoarthritis, as well as cancer and cardiovascular conditions. The amino acid sequence of TIMP-3 and the nucleic acid sequence of DNA encoding TIMP-3 are disclosed in U.S. Patent No. 6,562,596, issued May 13, 2003, the disclosure of which is incorporated herein by reference. Descriptions of TIMP mutations can be found in U.S. Patent Application Publication No. 2014 / 0274874 and WO 2014 / 152012.
[0075] Also included are antagonistic antibodies of the human calcitonin gene-related peptide (CGRP) receptor and bispecific antibody molecules targeting the CGRP receptor and other headache targets. Further information regarding these molecules can be found in PCT Publication WO 2010 / 075238.
[0076] Additionally, bispecific T cell engaging (BiTE®) antibodies, such as BLINCYTO® (blinatumomab), can be used in the device. Alternatively, an APJ macromolecule agonist, such as apelin or an analog thereof, can be included in the device. Information regarding such molecules can be found in PCT Publication WO 2014 / 099984.
[0077] In certain embodiments, the medicament comprises a therapeutically effective amount of anti-thymic stromal lymphopoietin (TSLP) or TSLP receptor antibody. Examples of anti-TSLP antibodies that may be used in such embodiments include, but are not limited to, those described in U.S. Patent Nos. 7,982,016 and 8,232,372, and U.S. Patent Publication No. 2009 / 0186022. Examples of anti-TSLP receptor antibodies include, but are not limited to, those described in U.S. Patent No. 8,101,182. In a particularly preferred embodiment, the medicament comprises a therapeutically effective amount of the anti-TSLP antibody designated A5 in U.S. Patent No. 7,982,016.
[0078] The drug delivery devices, methods, and components thereof have been described in terms of exemplary, but not limiting, embodiments. The detailed description is to be construed as an example only and does not describe all possible embodiments of the invention, since describing every single possible embodiment would be impractical, if not impossible. Numerous alternative embodiments can be implemented using either current technology or technology developed after the filing date of this patent, and such embodiments still fall within the scope of the claims that define the invention. For example, components described herein with respect to certain drug delivery devices, such as on-body injector drug delivery devices or other types of drug delivery devices, can also be utilized in other types of drug delivery devices, such as autoinjector drug delivery devices.
[0079] Those skilled in the art will understand that numerous modifications, alterations, and combinations can be made to the above-described embodiments without departing from the scope of the present invention, and such modifications, alterations, and combinations are to be construed as falling within the scope of the inventive concept.
Claims
1. 1. A drug delivery device comprising: a housing defining a shell having a proximal end, a distal end and a longitudinal axis extending between said proximal end and said distal end; a needle assembly at least partially disposed within the housing at the proximal end of the shell, the needle assembly including a syringe containing a medicament and a needle or cannula; a drive assembly disposed at least partially within the housing and operably coupled to the needle assembly, the drive assembly being movable between an initial position and a second position that effects ejection of the medicament from the syringe; an audible indicator operatively coupled to the drive assembly such that when the drive assembly is positioned in the second position, the audible indicator engages the drive assembly to produce an audible sound indicating that the medication has been expelled from the syringe; A drug delivery device comprising:
2. The drug delivery device of claim 1 , wherein the audible indicator is adapted to at least partially disengage from the drive assembly at the initiation of movement of the drive assembly from the first position toward the second position.
3. 3. The drug delivery device of claim 1, wherein the drive assembly comprises a plunger rod having a first end, a second end, and a first detent positioned at the second end.
4. 4. The drug delivery device of claim 3, wherein the plunger rod further comprises a second detent positioned a distance between the first end and the second end.
5. The drug delivery device of any one of claims 1 to 4, wherein the audible indicator comprises a resilient ring having an engagement tab.
6. The drug delivery device of claim 5 , wherein the audible indicator is made from at least one of a polymeric or metallic material.
7. 5. The drug delivery device of claim 1, wherein the drive assembly further comprises a magnetic member, and the audible indicator comprises a metallic member such that when the drive assembly is positioned at the second position, the metallic member engages the magnet to produce the audible sound.
8. The drug delivery device of any one of claims 1 to 7, wherein the audible indicator is in a relaxed configuration when the drive assembly is in the second position.
9. The drug delivery device of any one of claims 1 to 8, wherein the audible indicator is in a relaxed configuration when the drive assembly is in the initial position.
10. 1. A drug delivery device comprising: a housing defining a shell having a proximal end, a distal end and a longitudinal axis extending between said proximal end and said distal end; a needle assembly at least partially disposed within the housing at the proximal end of the shell, the needle assembly including a syringe containing a medicament and a needle or cannula; a drive assembly disposed at least partially within the housing and operably coupled to the needle assembly, the drive assembly being movable between an initial position and a second position that effects ejection of the medicament from the syringe; an audible indicator operatively coupled to the drive assembly such that upon completion of delivery of the medicament through the needle assembly, the audible indicator engages the drive assembly to produce an audible sound indicating that the medicament has been expelled from the syringe; A drug delivery device comprising:
11. The drug delivery device of claim 10 , wherein the audible indicator at least partially disengages from the drive assembly when delivery of the medicament begins.
12. 12. The drug delivery device of claim 10 or 11, wherein the drive assembly comprises a plunger rod having a first end, a second end, and a first detent positioned at the second end.
13. The drug delivery device of claim 12, wherein the drive assembly further comprises a second detent positioned a distance between the first end and the second end.
14. The drug delivery device of any one of claims 10 to 13, wherein the audible indicator comprises a resilient ring having an engagement tab.
15. The drug delivery device of claim 14 , wherein the audible indicator is made from at least one of a polymeric or metallic material.
16. 14. The drug delivery device of claim 10, wherein the drive assembly further comprises a magnetic member, and the audible indicator comprises a metallic member such that the metallic member engages the magnetic member to produce the audible sound when the drive assembly is positioned at the second position.
17. The drug delivery device of any one of claims 10 to 16, wherein the audible indicator is in a relaxed configuration when the drive assembly is in the second position.
18. The drug delivery device of any one of claims 10 to 17, wherein the audible indicator is in a relaxed configuration when the drive assembly is in the initial position.
Citation Information
Patent Citations
Injection equipment
JP2011520545A
A medical automated injection device for manual needle insertion, featuring a needle shield, attenuation mechanism, and auditory and tactile feedback.
JP2013534164A
Automatic drug injection device that audibly displays the injection progress
JP2017534392A
Hydraulic system
JP2021517943A
